# IMIDAZOHETEROCYCLIC COMPOUNDS PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

## Claims
Imidazo heterocyclische Verbindungen der Formel

## Description
The present invention relates to novel imidazoheterocyclic compounds and pharmaceutically acceptable salt thereof. More particularly, it relates to novel imidazoheterocyclic compounds and pharmaceutically acceptable salts thereof which have antiulcerative activity, to processes for preparation thereof, to a pharmaceutical composition comprising the same. EP A 0 033 094 discloses imidazo 1,2 a pyridines and 2,3 dihydro , 5,6,7,8 tetrahydro , 2,3,5,6,7,8 hexahydro analogues and salts of such compounds. Also the process for preparing the compounds and pharmaceutical compositions containing them are disclosed. It is described that the compounds are antisecretory and cytoprotective agents and are particularly useful in the treatment of ulcer diseases. Accordingly, one object of the present invention is to provide novel imidazoheterocyclic compounds and pharmaceutically acceptable salt thereof, which are useful as an antiulcerative agent. Another object of the present invention is to provide processes for preparation of said imidazoheterocyclic compounds and salts thereof. A further object of the present invention is to provide a pharmaceutical composition comprising, as an active ingredient, said imidazoheterocyclic compound or its pharmaceutically acceptable salt. Still further object of the present invention is to provide a method of using said imidazoheterocyclic compound or its pharmaceutically acceptable salt in the treatment of ulcer in human or animals. The imidazoheterocyclic compounds of the present invention are novel and can be represented by the formula I wherein According to the present invention, the object compounds I can be prepared by the following processes. wherein As to the starting compounds II , III and IV , some of them are novel and can be prepared by the procedures disclosed in the Preparations as mentioned later. wherein Suitable pharmaceutically acceptable salts of the object compounds I are conventional non toxic salts and include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt e.g. sodium salt or potassium salt , an alkaline earth metal salt e.g. calcium salt or magnesium salt , an ammonium salt a salt with an organic base, for example, or an organic amine salt e.g. triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, or N,N dibenzylethylenediamine salt an organic acid addition salt e.g. acetate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, or toluenesulfonate , an inorganic acid addition salt e.g. hydrochloride, hydrobromide, sulfate, or phosphate , or a salt with an amino acid e.g. arginine, aspartic acid, glutamic acid . In the above and subsequent descriptions of the present specification, suitable examples and illustrations of the various definitions which the present invention includes within the scope thereof are explained in detail as follows. Suitable C₁ C₆ alkyl may include methyl, ethyl, propyl, isopropyl, n butyl, t butyl, pentyl or hexyl, in which the preferred one may be C₁ C₄alkyl and the more preferred one may be methyl and ethyl. Suitable C₂ C₆ alkenyl Suitable C₂ C₆ alkynyl Suitable C₃ C₆ alkadienyl Cumulated C₃ C₆ alkadienyl means the above defined C₃ C₆ alkadienyl group in which two double bonds are adjacent to each other through one carbon atom, and suitable examples of such cumulated C₃ C₆ alkadienyl may include 1,2 propadienyl, 1,2 butadienyl, 2,3 pentadienyl, or 1,2 hexadienyl, In the term C₂ C₆ alkenyloxy C₁ C₆ alkyl , suitable C₂ C₆ alkenyl moiety and C₁ C₆ alkyl moiety can be referred to the ones as mentioned above, respectively, and suitable examples of such C₂ C₆ alkenyloxy C₁ C₆ alkyl may include vinyloxymethyl, allyloxymethyl, 1 allyloxyethyl, 1 allyloxypropyl, 3 allyloxybutyl, 3 2 butenyloxy butyl, 5 3 pentenyloxy pentyl, or 1 2 hexenyloxy hexyl, in which the preferred one may be C₂ C₄ alkenyloxy C₁ C₄ alkyl and the more preferred one may be allyloxymethyl. In the term C₂ C₆ alkynyloxy C₁ C₆ alkyl , suitable C₂ C₆ alkynyl moiety and C₁ C₆ alkyl moiety can be referred to the ones as mentioned above, respectively, and suitable examples of such C₂ C₆ alkynyloxy C₁ C₆ alkyl may include ethynyloxymethyl, 2 propynyloxymethyl, 2 2 propynyloxy ethyl, 1 2 butynyloxy propyl, 1 3 butynyloxy propyl, 2 3 butynyloxy butyl, 3 3 butynyloxy butyl, 4 1 pentynyloxy pentyl, 4 4 pentynyloxy pentyl, 5 5 hexynyloxy hexyl, or 6 5 hexynyloxy hexyl, Carboxy C₂ C₆ alkynyloxy C₁ C₆ alkyl means the above defined C₂ C₆ alkynyloxy C₁ C₆ alkyl group which is substituted with carboxy, and suitable examples of such carboxy C₂ C₆ alkynyloxy C₁ C₆ alkyl may include carboxyethynyloxymethyl, 3 carboxy 2 propynyloxymethyl, 1 carboxy 2 propynyloxymethyl, 2 3 carboxy 2 propynyloxy ethyl, 1 1 carboxy 2 butynyloxy propyl, 1 4 carboxy 3 butynyloxy propyl, 2 4 carboxy 3 butynyloxy butyl, 3 4 carboxy 3 butynyloxy butyl, 4 3 carboxy 1 pentynyloxy pentyl, 4 5 carboxy 4 pentynyloxy pentyl, 5 1 carboxy 5 hexynyloxy hexyl, or 6 6 carboxy 5 hexynyloxy hexyl, in which the preferred one may be carboxy C₂ C₄ alkynyloxy C₁ C₄ alkyl and the more preferred one may be 3 carboxy 2 propynyloxymethyl. Suitable examples of C₁ C₆ alkoxycarbonyl C₂ C₆ alkynyloxy C₁ C₆ alkyl may be methoxycarbonylethynyloxymethyl, 3 ethoxycarbonyl 2 propynyloxymethyl, 1 ethoxycarbonyl 2 propynyloxymethyl, 2 3 ethoxycarbonyl 2 propynyloxy ethyl, 1 1 propoxycarbonyl 2 butynyloxy propyl, 1 4 ethoxycarbonyl 3 butynyloxy propyl, 2 4 butoxycarbonyl 3 butynyloxy butyl, 3 4 tert butoxycarbonyl 3 butynyloxy butyl, 4 3 pentyloxycarbonyl 1 pentynyloxy pentyl, 4 5 ethoxycarbonyl 4 pentynyloxy pentyl, 5 1 hexyloxycarbonyl 5 hexynyloxy hexyl, or 6 6 hexyloxycarbonyl 5 hexynyloxy hexyl, in which the preferred one may be C₁ C₄ alkoxycarbonyl C₂ C₄ alkynyloxy C₁ C₄ alkyl and the more preferred one may be 3 ethoxycarbonyl 2 propynyloxymethyl. Suitable carboxy C₂ C₆ alkynyl may be the same as that in the terms of carboxy C₂ C₆ alkynyloxy C₁ C₆ alkyl and may include carboxyethynyl, 3 carboxy 2 propynyl, 1 carboxy 2 propynyl, 1 carboxy 2 butynyl, 4 carboxy 3 butynyl, 3 carboxy 1 pentynyl, 1 carboxy 5 hexynyl, or 6 carboxy 5 hexynyl, in which the preferred one may be carboxy C₂ C₄ alkynyl and the more preferred one may be 3 carboxy 2 propynyl. Suitable C₁ C₆ alkoxycarbonyl C₂ C₆ alkynyl may include methoxycarbonylethynyl, 3 ethoxycarbonyl 2 propynyl, 1 ethoxycarbonyl 2 propynyl, 1 propoxycarbonyl 2 butynyl, 4 ethoxycarbonyl 3 butynyl, 4 butoxycarbonyl 3 butynyl, 4 tert butoxycarbonyl 3 butynyl, 3 pentyloxycarbonyl 1 pentynyl, 1 hexyloxycarbonyl 5 hexynyl, or 6 hexyloxycarbonyl 5 hexynyl, in which the preferred one may be C₁ C₄ alkoxycarbonyl C₂ C₄ alkynyl and the more preferred one may be 3 ethoxycarbonyl 2 propynyl. ω C₂ C₆ Alkynyloxy C₁ C₆ alkyl means the above defined lower alkynyloxy C₁ C₆ alkyl group, in which the triple bond always exists on the terminal carbon atom of the C₂ C₆ alkynyl moiety, and suitable examples of such ω C₂ C₆ alkynyloxy C₁ C₆ alkyl may include ethynyloxymethyl, 2 propynyloxymethyl, 2 2 propynyloxy ethyl, 1 3 butynyloxy propyl, 2 3 butynyloxy butyl, 4 4 pentynyloxy pentyl, or 6 5 hexynyloxy hexyl, in which the preferred one may be ω C₂ C₄ alkynyloxy C₁ C₄ alkyl and the more preferred one may be 2 propynyloxymethyl. ω Carboxy ω C₂ C₆ alkynyloxy C₁ C₆ alkyl means the above defined ω C₂ C₆ alkynyloxy C₁ C₆ alkyl group which is substituted with carboxy on the terminal carbon atom of the C₂ C₆ alkynyl moiety, and suitable examples of such ω carboxy ω C₂ C₆ alkynyloxy C₁ C₆ alkyl may include carboxyethynyloxymethyl, 3 carboxy 2 propynyloxymethyl, 2 3 carboxy 2 propynyloxy ethyl, 1 4 carboxy 3 butynyloxy propyl, 2 4 carboxy 3 butynyloxy butyl, 4 5 carboxy 4 pentynyloxy pentyl, or 6 6 carboxy 5 hexynyloxy hexyl, in which the preferred one may be ω carboxy ω C₂ C₄ alkynyloxy C₁ C₄ alkyl and the more preferred one may be 3 carboxy 2 propynyloxymethyl. Suitable aryl may include phenyl, tolyl, xylyl, 1 naphthyl, 2 naphthyl, 1 anthryl, or 2 anthryl, Suitable ar C₁ C₆ alkyl may include mono or di or tri phenyl C₁ C₆ alkyl such as benzyl, 1 phenylethyl, 2 phenylethyl, 2 phenylpropyl, 3 phenylbutyl, 1 methyl 2 phenylpropyl, 5 phenylpentyl, 4 phenylhexyl, benzhydryl, 2,3 diphenylpropyl, trityl, or 1,2,3 triphenylbutyl or naphthyl C₁ C₆ alkyl such as 1 naphthylmethyl, 2 naphthylmethyl, 1 2 naphthyl ethyl, 3 1 naphthyl propyl, 2 2 naphthyl butyl, 5 1 naphthyl pentyl, or 4 2 naphthyl hexyl Said ar C₁ C₆ alkyl may have one or more preferably 1 to 3 suitable substituent s selected from a group consisting of C₁ C₆ alkyl e.g. methyl, ethyl, propyl, isopropyl, butyl, pentyl, or hexyl and halogen e.g. fluoro, chloro, bromo, iodo , and the preferred examples of said substituted ar C₁ C₆ alkyl may be mono or di halophenyl lower alkyl e.g. 2 chlorobenzyl, 3 chlorobenzyl, 4 chlorobenzyl, 2 bromobenzyl, 4 bromobenzyl, 2 fluorobenzyl, 4 fluorobenzyl, 4 iodobenzyl, 2 chlorophenethyl, 2,3 dichlorobenzyl, 2,4 dichlorobenzyl, 3,4 dichlorobenzyl, 2,6 dichlorobenzyl, 2 chloro 4 fluorobenzyl, mono or di C₁ C₆ alkylphenyl C₁ C₆ alkyl e.g. 2 methylbenzyl, 3 methylbenzyl, 4 methylbenzyl, 2 methylphenethyl, 2 ethylbenzyl, 2 propylbenzyl, 2 isopropylbenzyl, 3 butylbenzyl, 4 pentylbenzyl, 2 hexylbenzyl, 2,3 dimethylbenzyl, 2,6 dimethylbenzyl, 2,4 diethylbenzyl, or 2 methyl 4 propylbenzyl , and the more preferred one may be mono or dihalophenyl C₁ C₄ alkyl and mono or di C₁ C₄ alkyl phenyl C₁ C₄ alkyl, and the most preferred one may be 2 chlorobenzyl, 3 chlorobenzyl, 2 bromobenzyl, 2 fluorobenzyl, 2,4 dichlorobenzyl, 3,4 dichlorobenzyl, 2,6 dichlorobenzyl, 2 methylbenzyl, 2 ethylbenzyl, 2 isopropylbenzyl and 2,6 dimethylbenzyl. Suitable ar C₂ C₆ alkenyl may include mono or di or tri phenyl C₂ C₆ alkenyl such as styryl, cinnamyl, phenylbutenyl e.g. 4 phenyl 2 butenyl, or 2 phenyl 3 butenyl, phenylpentenyl e.g. 1 phenyl 1 pentenyl, phenylhexenyl e.g. 4 phenyl 2 hexenyl, 2,3 diphenyl 1 butenyl, or 2,3,4 triphenyl 4 pentenyl, in which the preferred one may be phenyl C₂ C₄ alkenyl and the more preferred one may be cinnamyl. Suitable benzene condensed cyclo C₅ C₆ alkyl may include naphthyl, 1,4 dihydronaphthyl, indenyl, benzene condensed cyclo C₅ C₆ alkyl e.g. 1,2,3,4 tetrahydronaphthyl, 2,3 dihydroindenyl, or perhydroindenyl in which the preferred one may be benzene condensed cyclo C₅ C₆ alkyl and the more preferred one may be 1,2,3,4 tetrahydronaphthyl. Suitable C₁ C₆ alkyl having cyclo C₃ C₆ alkyl may include cyclopropylmethyl, cyclobutylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, or cyclohexylhexyl, in which the preferred one may be cyclo C₅ C₆ alkyl C₁ C₄ alkyl and the more preferred one may be cyclohexylmethyl. Suitable C₁ C₆ alkylene may include methylene, ethylene, trimethylene, propylene, tetramethylene, pentamethylene, or hexamethylene in which the preferred one may be C₁ C₄alkylene and the more preferred one may be methylene. Suitable an acid residue may include halogen e.g. fluorine, chlorine, bromine, iodine , or acyloxy e.g. acetoxy, tosyloxy, mesyloxy, etc. . Suitable a leaving group may include an acid residue as mentioned above, a group of the formula wherein The processes for preparing the object compounds of the present invention are explained in detail in the following. The object compound I or a salt thereof can be prepared by reacting the compound II or a salt thereof with the compound III or a salt thereof. Suitable salts of the compound II can be referred to the acid addition salt as exemplified for the compound I and those of the compound III can be referred to the salt with a base for the same. This reaction is usually carried out in a solvent such as alcohol e.g. methanol, or ethanol, benzene, N,N dimethylformamide, tetrahydrofuran, diethyl ether or any other solvent which does not adversely affect the reaction. The reaction may be carried out in the presence of an inorganic or an organic base such as an alkali metal hydroxide e.g. sodium hydroxide, or potassium hydroxide , an alkali metal carbonate e.g. sodium carbonate, or potassium carbonate , an alkali metal bicarbonate e.g. sodium bicarbonate, or potassium bicarbonate , tri C₁ C₆ alkylamine e.g. trimethylamine, or triethylamine , pyridine or its derivative e.g. picoline, lutidine, or 4 dimethylaminopyridine , In case that the base to be used is liquid, it can also be used as a solvent. The reaction temperature is not critical, and the reaction can be carried out under cooling, at ambient temperature or under warming or heating. The object compound Ib or a salt thereof can be prepared by subjecting the compound Ia or a salt thereof to isomerization reaction of C₂ C₆ alkynyl into cumulated C₃ C₆ alkadienyl. Suitable salts of the compounds Ia and Ib can be referred to the acid addition salts as exemplified for the compound I . This reaction is usually carried out in the presence of a base such as an alkali metal hydroxide e.g. sodium hydroxide, or potassium hydroxide, or an alkali metal carbonate e.g. sodium carbonate, potassium carbonate . This reaction is usually carried out in a solvent such as alcohol e.g. methanol, or ethanol . N,N dimethylformamide or any other solvent which does not adversely affect the reaction. The reaction temperature is not critical, and the reaction can be carried out at ambient temperature or under warming or heating. The object compound Ic or a salt thereof can be prepared by reacting the compound IV or a salt thereof with the compound V or a salt thereof. Suitable salts of the compound IV can be referred to the acid addition salts as exemplified for the object compound I . Suitable salts of the compound Ic can be referred to the ones as exemplified for the object compound I . Suitable salts of the compound V are salts with a base such as an alkali metal salt e.g. sodium salt, potassium salt, or lithium salt . This reaction is usually carried out in the presence of a base such as alkali metal hydride e.g. sodium hydride, potassium hydride, or lithium hydride , alkali metal alkoxide e.g. potassium t butoxide or an alkali metal e.g. sodium, or potassium, lithium . This reaction is usually carried out in a solvent such as alcohol e.g. methanol, or ethanol , dimethyl sulfoxide, benzene, N,N dimethylformamide, tetrahydrofuran, diethyl ether or any other solvent which does not adversely affect the reaction. In case that the compound V or a salt thereof to be used is liquid, it can also be used as a solvent. The reaction temperature is not critical, and the reaction can be carried out under cooling, at ambient temperature or under warming or heating. The object compound Ie or a salt thereof can be prepared by subjecting the compound Id or a salt thereof to acylation reaction. Suitable salts of the compound Id can be referred to the acid addition salts as exemplified for the compound I . Suitable salts of the compound Ie can be referred to the ones as exemplified for the compound I . The acylation reaction of this process can be carried out by reacting the compound Id or a salt thereof with a conventional agent which can introduce a carboxy or a protected carboxy group into a terminal carbon atom of C₂ C₆ alkynyl such as carbon dioxide gas, dry ice, C₁ C₆ alkoxy halo formate e.g. ethyl chloroformate, di C₁ C₆ alkyl carbonate e.g. dimethyl carbonate, or diethyl carbonate , di C₁ C₆ alkyl oxalate e.g. diethyl oxalate or tri C₁ C₆ alkyl phosphonoacetate e.g. triethyl phosphonoacetate . This reaction is usually carried out in the presence of a base such as metalated C₁ C₆ alkyl e.g. methyl lithium, or n butyl lithium , metalated aryl e.g. phenyl lithium , or alkali metal hydride e.g. sodium hydride, or potassium hydride . This reaction is usually carried out in a solvent such as diethyl ether, tetrahydrofuran, N,N dimethylformamide, n hexane or any other solvent which does not adversely affect the reaction. The reaction temperature is not critical, and the reaction can be carried out under cooling or at ambient temperature. The object compounds I and their pharmaceutically acceptable salts of the present invention are novel and exhibit high antiulcerative activity. In order to illustrate the usefulness of the object compounds I , the pharmacological data of some representative compounds of the object compounds I are shown in the following. Five male Sprague Dawley rats, aged 7 weeks and weighing about 200 g, were used per group for the study on ethanol ulcer after the fast for 24 hours. Test compound was suspended in 0.1 methylcellulose aqueous solution, and the suspension 5 ml kg was orally given to each rat. The control group was given a vehicle, i.e. 0.1 methylcellulose aqueous solution 5 ml kg , alone in the same way. Absolute ethanol 5 ml kg was orally administered 30 minutes after dosing with test compound, and one hour later, the rats were sacrificed and their stomachs were removed. The area of ulcers of each rat was measured. The mean area mm in the medicated group was compared with that in the control group. Five Sprague Dawley rats weighing about 200 g were used per group. Each animal was immobilized in a small cage and put in a water bath allowing to respire. The temperature of the water bath kept at 22 C. The test compound was administered orally just before the immobilization. Seven hours later, the animals were sacrificed and their stomachs were removed. The stomach was then fixed with 2 formalin. The area of ulcers was measured for each animal. The mean area mm² in the medicated animals was compared with that in the control animals. As being apparent from the above test results, the object compound I of the present invention are useful as an antiulcerative agent. For therapeutic purpose, the compounds according to the present invention can be used in a form of pharmaceutical preparation containing said compound as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral or parenteral administration. The pharmaceutical preparations may be capsules, tablets, dragees, solution, suspension, emulsion, and the like. If desired, there may be included in the above preparations auxiliary substances, stabilizing agents, wetting or emulsifying agents, buffers and other commonly used additives. While the dosage of the compounds will vary depending upon the age and condition of the patient, an average single dose of about 5 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg, and 1000 mg of the compounds according to the present invention may be effective for treating ulcer. In general, amounts between 1 mg body and about 2,000 mg body or even more may be administered per day. The following preparations and examples are given for the purpose of illustrating the present invention. A solution of 5 hexen 2 one 3.92 g in N,N dimethylformamide 4 ml was added to mixture of cupric chloride dihydrate 13.636 g and lithium chloride 3.392 g in N,N dimethylformamide 20 ml at 80 C. After being stirred at 80 90 C for 1 hour, the mixture was poured into cold water and extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and evaporated in vacuo to give a crude oil of 3 chloro 5 hexen 2 one 3.01 g which was used for the next step without purification. Tosyl chloride 3.81 g was added to a solution of 3 hydroxy 5 hexyn 2 one 2.24 g and triethylamine 2.424 g in methylene chloride 20 ml under ice cooling. After being stirred for 2.5 hours, the mixture was washed with water, dried over magnesium sulfate and evaporated in vacuo. The oily residue was purified by column chromatography on silica gel 60 g using methylene chloride as an eluent to give an oil of 3 tosyloxy 5 hexyn 2 one 2.94 g . Mesyl chloride 1.73 ml was added dropwise to a solution of 3 hydroxy 2 methoxy 1 hexen 5 yne 2 g and triethylamine 3.32 ml in methylene chloride 20 ml under ice cooling over a period of 10 minutes. After being stirred for 48 hours at room temperature the mixture was washed successively with water, aqueous sodium bicarbonate solution, and brine, dried over magnesium sulfate, and evaporated in vacuo to give 3 mesyloxy 2 methoxy 1 hexen 5 yne 3.45 g . To a solution of 3 mesyloxy 2 methoxy 1 hexen 5 yne 0.5 g in acetone 1.5 ml was added 20 sulfuric acid 1.5 ml under ice cooling and the mixture was stirred for 1.5 hours under the same conditions and then for 1.5 hours at room temperature. Acetone was evaporated in vacuo and the residue was extracted with methylene chloride. The extract was washed successively with water, aqueous sodium bicarbonate solution, and brine, dried over magnesium sulfate, and evaporated in vacuo to give 3 mesyloxy 5 hexyn 2 one 0.41 g . To a mixture of 2 amino 3 hydroxypyridine 7 g and Adogen 464 Trademark prepared by Aldrich Chemical Co. 0.4 g in 40 aqueous sodium hydroxide 32 ml and methylene chloride 32 ml was added 2 methylbenzyl chloride 8.42 ml at ambient temperature. After being stirred for 24 hours, the organic layer was separated and the aqueous layer was extracted with methylene chloride. The combined extracts were washed with saturated sodium chloride aqueous solution, dried over magnesium sulfate, and evaporated in vacuo. The crystalline residue was recrystallized from ethyl acetate to give 2 amino 3 2 methylbenzyloxy pyridine 7.56 g . The following compounds were prepared according to a similar manner to that of Preparation 5. Molecular Sieves 16 g was added to a solution of 2,3 diaminopyridine 8 g , 2 methylbenzaldehyde 8.81 g , and acetic acid 4.2 ml in methanol 160 ml and the mixture was stirred for 96 hours at room temperature. Sodium cyanoborohydride 4.61 g was added portionwise to the mixture with stirring under ice cooling over a period of 20 minutes. After being stirred for 3 hours, the mixture was made alkaline with aqueous sodium bicarbonate solution and filtered by suction. The filtrate was evaporated in vacuo, and to the residue was added water and then extracted with methylene chloride. The extract was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The crystalline residue was recrystallized from a mixture of ethyl acetate and n hexane to give 2 amino 3 2 methylbenzylamino pyridine 5.38 g . 2 Amino 3 2 chlorobenzylamino pyridine was obtained according to a similar manner to that of Preparation 7. To a solution of 2 methylbenzyl alcohol 0.985 g in N,N dimethylformamide 10 ml was added 62.8 sodium hydride 0.308 g under a nitrogen atmosphere and then stirred for 30 minutes. 2 Amino 3 chloropyrazine 0.87 g was added to the solution and the mixture was heated at 65 C for 2 hours and poured onto crushed ice. The resulting precipitates were collected by filtration, washed with n hexane, and dried in a desiccator to give 2 amino 3 2 methylbenzyloxy pyrazine 0.6 g . A mixture of 2 amino 3 chloropyrazine 4.3 g , 2 methylbenzylamine 4.6 g , potassium carbonate 5.5 g , and potassium iodide 0.4 g in N,N dimethylformamide 43 ml was refluxed for 24 hours under a nitrogen atmosphere and allowed to stand at room temperature. The mixture was poured into water and extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel 110 g with a mixture of chloroform and methanol 100 3 as an eluent to give 2 amino 3 2 methylbenzylamino pyrazine 1.4 g . A 60 dispersion of sodium hydride in mineral oil 1.87 g was added portionwise to a suspension of 8 hydroxy 2 methylimidazo 1,2 a pyridine 6.3 g in dimethyl sulfoxide 63 ml at room temperature over a period of 15 minutes. After being stirred for 30 minutes, 2 chlorobenzyl chloride 7.54 g was added in one portion to the mixture and then the resultant mixture was stirred for 24 hours at room temperature. The mixture was poured into water and the resulting precipitate was collected by filtration. The crude product was purified by column chromatography on silica gel 30 g with methylene chloride as an eluent to afford a solid, which was recrystallized from a mixture of diethyl ether and n hexane to give 8 2 chlorobenzyloxy 2 methylimidazo 1,2 a pyridine 7.75 g . The following compounds were obtained according to a similar manner to that of Preparation 11. A solution of 2 amino 3 2 methylbenzylamino pyridine 3.25 g and chloroacetone 1.26 ml in ethanol 65 ml was refluxed for 18 hours and then evaporated in vacuo. To the residue was added aqueous sodium bicarbonate solution and the mixture was extracted with methylene chloride. The extract was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The oily residue was purified by column chromatography on silica gel 40 g with a mixture of methylene chloride and ethyl acetate 10 1 as an eluent to give 8 2 methylbenzylamino 2 methylimidazo 1,2 a pyridine 1.80 g . 8 2 Chlorobenzylamino 2 methylimidazo 1,2 a pyridine was obtained according to a similar manner to that of Preparation 13. To a solution of 37 aqueous formaldehyde 2.38 g in acetic acid 38 ml was added dropwise 50 aqueous dimethylamine 2.63 g with ice cooling over a period of 10 minutes and the mixture was stirred for an additional 10 minutes. The mixture was heated at 50 55 C for 2 hours after an addition of 8 2 chlorobenzyloxy 2 methylimidazo 1,2 a pyridine 7.6 g thereto and then evaporated in vacuo. The residue was basified with aqueous sodium hydroxide and extracted with methylene chloride. The extract was washed with water, dried over magnesium sulfate and evaporated in vacuo. The residual solid was recrystallized from a mixture of diethyl ether and n hexane to give 8 2 chlorobenzyloxy 3 dimethylaminomethyl 2 methylimidazo 1,2 a pyridine 7.85 g . The following compounds were obtained according to a similar manner to that of Preparation 15. Methyl iodide 3.48 g was added dropwise to a solution of 8 2 chlorobenzyloxy 3 dimethylaminomethyl 2 methylimidazo 1,2 a pyridine 7.8 g in acetone 100 ml at room temperature and the mixture was stirred for 24 hours. The resulting precipitate was collected by filtration, washed with acetone, and dried in a desiccator to give 8 2 chlorobenzyloxy 3 trimethylammoniomethyl 2 methylimidazo 1,2 a pyridine iodide 11.35 g . The following compounds were obtained according to a similar manner to that of Preparation 17. A solution of 2 amino 3 benzyloxypyridine 3 g and 3 chloro 5 hexen 2 one 2.981 g in ethanol 15 ml was stirred and refluxed for 45 hours and then evaporated in vacuo. To the residue was added an aqueous solution of sodium bicarbonate and the mixture was extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and evaporated in vacuo. The oily residue was purified by column chromatography on silica gel 50 g using methylene chloride and then chloroform as eluents. The eluate with chloroform was evaporated in vacuo and the residual solid was recrystallized from diisopropyl ether to give 8 benzyloxy 3 allyl 2 methylimidazo 1,2 a pyridine 0.31 g . A solution of 2 amino 3 benzyloxypyridine 2 g and 3 tosyloxy 5 hexyn 2 one 2.66 g in ethanol 15 ml was stirred and refluxed for 24 hours and then evaporated in vacuo. To the residue was added an aqueous solution of sodium bicarbonate and the mixture was extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and evaporated in vacuo. The oily residue was purified by column chromatography on silica gel 50 g using chloroform as an eluent to give a solid, which was recrystallized from a mixture of methylene chloride and diethyl ether to give 8 benzyloxy 3 2 propynyl 2 methylimidazo 1,2 a pyridine 0.855 g . 8 2 Phenylethoxy 3 2 propynyl 2 methylimidazo 1,2 a pyridine was obtained by reacting 2 amino 3 2 phenylethoxy pyridine with 3 mesyloxy 5 hexyn 2 one according to similar manners to those of Examples 1 and 2. A solution of 2 amino 3 2 methylbenzyloxy pyridine 5 g and 3 tosyloxy 5 hexyn 2 one 7.45 g in ethanol 35 ml was heated under reflux for 28 hours and then evaporated in vacuo. The residue was dissolved in ethyl acetate and the solution was allowed to stand at ambient temperature. The resultant precipitate was collected by filtration and dissolved in a mixture of methylene chloride and aqueous sodium bicarbonate. The organic layer was separated, washed with saturated sodium chloride aqueous solution, treated with silica gel and activated charcoal successively, and evaporated in vacuo. The crystalline residue was recrystallized from ethyl acetate to give 8 2 methylbenzyloxy 3 2 propynyl 2 methylimidazo 1,2 a pyridine 1.44 g . The following compounds were prepared according to similar manners to those of Examples 1, 2, 3 and 4. A solution of 2 amino 3 2 methylbenzylamino pyridine 2 g and 3 mesyloxy 5 hexyn 2 one 1.78 g in ethanol 40 ml was refluxed for 31.5 hours and then evaporated in vacuo. The residue was treated with aqueous sodium bicarbonate solution and extracted with methylene chloride. The extract was washed with water, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel 40 g with a mixture of methylene chloride and ethyl acetate 50 1 to 10 1 as an eluent to give 8 2 methylbenzylamino 3 2 propynyl 2 methylimidazo 1,2 a pyridine 0.82 g . 8 2 Chlorobenzylamino 3 2 propynyl 2 methylimidazo 1,2 a pyridine was obtained according to a similar manner to that of Example 6. Sodium bicarbonate 2.73 g was added to a solution of 2 amino 3 2 methylbenzyloxy pyrazine 3.5 g and 3 mesyloxy 5 hexyn 2 one 6.18 g in ethanol 35 ml and the mixture was refluxed for 12 hours. The mixture was poured into an aqueous solution of sodium bicarbonate and extracted with chloroform. The extract was washed with water, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel 200 g with a mixture of chloroform and methanol 50 1 as an eluent to give 8 2 methylbenzyloxy 3 2 propynyl 2 methylimidazo 1,2 a pyrazine 0.182 g . 8 2 Methylbenzylamino 3 2 propynyl 2 methylimidazo 1,2 a pyrazine hydrochloride was obtained according to a similar manner to that of Example 8. IR Nujol 3350, 3180, 2560, 1660, 1635, 1525 cm ¹ A solution of 8 2 methylbenzyloxy 3 2 propynyl 2 methylimidazo 1,2 a pyridine 0.99 g and 1N sodium hydroxide solution 5.65 ml in methanol 50 ml was stirred for 72 hours at room temperature. The mixture was evaporated in vacuo and the residue was dissolved in chloroform. The solution was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel 14 g with a mixture of chloroform and ethyl acetate 15 1 as an eluent to give 8 2 methylbenzyloxy 3 1,2 propadienyl 2 methylimidazo 1,2 a pyridine 0.27 g . To a solution of sodium hydride 61 in mineral oil dispersion 7.39 g in 2 propynyl alcohol 300 ml was added 8 benzyloxy 3 trimethylammoniomethyl 2 methylimidazo 1,2 a pyridine iodide 74.6 g , and the mixture was heated at 90 95 C with stirring for 2.5 hours. After being cooled, the mixture was evaporated in vacuo and the residue was dissolved in methylene chloride. The solution was washed with water, dried over magnesium sulfate, and evaporated in vacuo. The oily residue was purified by column chromatography on Silica gel 200 g with methylene chloride as an eluent and the fractions containing the object compound were combined. The resultant solution was treated with a solution of hydrogen chloride in ethanol to give 8 benzyloxy 3 2 propynyloxymethyl 2 methylimidazo 1,2 a pyridine hydrochloride 37.5 g . A solution of 8 benzyloxy 3 2 propynyloxymethyl 2 methylimidazo 1,2 a pyridine hydrochloride 35.5 g in hot water 700 ml was neutralized with aqueous sodium hydroxide solution and extracted with methylene chloride. The extract was washed with water, dried over magnesium sulfate, treated with activated charcoal, and evaporated in vacuo. The residual solid was recrystallized from a mixture of methylene chloride and n hexane to give 8 benzyloxy 3 2 propynyloxymethyl 2 methylimidazo 1,2 a pyridine 26.03 g . To a solution of sodium hydride 63.6 in mineral oil dispersion, 0.285 g in 2 propynyl alcohol 12 ml was added 8 2 methylbenzyloxy 3 trimethylammoniomethyl 2 methylimidazo 1,2 a pyridine iodide 3 g and the mixture was heated at 85 100 C for 1.5 hours. After being cooled, the mixture was poured into ice water and the resulting precipitate was collected by filtration and dissolved in methylene chloride. The solution was treated successively with silica gel 4.5 g and activated charcoal and evaporated in vacuo. The crystalline residue was recrystallized from a mixture of ethyl acetate and petroleum ether to give 8 2 methylbenzyloxy 3 2 propynyloxymethyl 2 methylimidazo 1,2 a pyridine 1.18 g . To a solution of sodium hydride 60 in mineral oil dispersion, 0.186 g in 2 propynyl alcohol 8 ml was added 8 2 chlorobenzyloxy 3 trimethylammoniomethyl 2 methylimidazo 1,2 a pyridine iodide 2 g and the mixture was heated at 90 95 C with stirring for 1 hour. After being cooled, the mixture was poured into ice water and the resulting precipitate was collected by filtration and dissolved in methylene chloride. The solution was treated successively with silica gel 1 g and activated charcoal and evaporated in vacuo. The crystalline residue was recrystallized from a mixture of methylene chloride and n hexane to give 8 2 chlorobenzyloxy 3 2 propynyloxymethyl 2 methylimidazo 1,2 a pyridine 0.9 g . The following compounds were obtained according to similar manners to those of Examples 11, 13 and 14. To a solution of 8 benzyloxy 3 2 propynyloxymethyl 2 methylimidazo 1,2 a pyridine 1 g in tetrahydrofuran 10 ml was added dropwise 10 solution of n butyllithium in n hexane 2.09 ml at 60 C under a nitrogen atmosphere. After being stirred for 10 minutes the solution was treated with dry ice 1.4 g , allowed to warm to room temperature, and acidified with diluted acetic acid. The resulting precipitates were collected by filtration, washed with water, and recrystallized from methanol to give 8 benzyloxy 3 3 carboxy 2 propynyloxymethyl 2 methylimidazo 1,2 a pyridine 0.67 g . 8 Benzyloxy 3 3 ethoxycarbonyl 2 propynyloxymethyl 2 methylimidazo 1,2 a pyridine was obtained by reacting 8 benzyloxy 3 2 propynyloxymethyl 2 methylimidazo 1,2 a pyridine with ethyl chloroformate according to a similar manner to that of Example 16.